Managing Advanced and Metastatic Disease

A diagnosis of metastatic (advanced) HER2-positive breast cancer is a life-altering event. While metastatic disease is generally not considered curable, it is highly treatable. The goals of care are to control the disease, relieve symptoms, and prolong life. With modern therapies, patients are living significantly longer, often maintaining good function for years ^[1][2].

The First-Line Approach

The goal of your first treatment (first-line therapy) for metastatic disease is to gain control over the cancer. The best choice depends heavily on what treatments you received in the past (e.g., for early-stage disease) and your current health.

• The Established Standard (THP): For over a decade, the standard first-line recommendation has been a combination of three drugs: a chemotherapy (usually a taxane) plus two HER2-targeted antibodies, trastuzumab and pertuzumab ^[3].
• Emerging Data (T-DXd): Recent results from a major trial (DESTINY-Breast09) have shown that using T-DXd (trastuzumab deruxtecan)—an antibody-drug conjugate (ADC)—plus pertuzumab kept cancer from growing for a median of 40.7 months, compared to 26.9 months with the THP regimen ^[4]. While this is strong evidence reshaping care, T-DXd carries a higher risk of a potentially serious lung inflammation called Interstitial Lung Disease (ILD) (12.1% in the T-DXd group vs 1% in the THP group) ^[4]. Your doctor will help you decide which first-line option is best based on current guidelines, your lung health, and drug availability in your region.

Second-Line and Beyond: Sequential Therapy

If a treatment stops working, your team has a sequence of other highly effective medications ready.

• Second-Line: If you did not receive it as your first treatment (or during early-stage care), T-DXd is often the preferred second-line therapy ^[3]. In clinical trials, it significantly outperformed the previous standard, T-DM1 (trastuzumab emtansine) ^[5][6].
• Third-Line and Later: Options include T-DM1 (if not used previously), combinations of chemotherapy with trastuzumab, or newer targeted drugs ^[3][7]. Because cancer biology can change, your doctor may occasionally recommend a biopsy of a metastatic site to reassess your HER2 and hormone receptor status.

Managing Brain Metastases

HER2-positive cancer has a known tendency to spread to the brain. Managing these metastases is a multidisciplinary effort ^[8].

• Systemic Therapy: A combination of tucatinib, trastuzumab, and the oral chemotherapy capecitabine is an important option. The HER2CLIMB trial showed this regimen improved outcomes for patients with brain metastases ^[9][10]. Tucatinib is a small molecule designed to cross the blood-brain barrier ^[11].
• Local Treatment: While systemic drugs are powerful, doctors heavily rely on localized treatments like stereotactic radiosurgery (SRS) or surgery to target specific lesions in the brain with high precision while sparing healthy tissue ^[12].

Advanced HER2-positive breast cancer is a fast-moving field of research. Your care team’s job is to select the right tool at the right time, balancing the power of these medications with your personal goals and quality of life.